Flow cytometric immunophenotyping (FCI) is a long-established method for diagnosis and classification of B-cell lymphomas. The method is rapidly evolving with better-performing flow cytometers. The development of markers is also fast. More and more laboratories around the world use 8-10 colored basic antibody (Ab) panels for the diagnosis of B-cell lymphomas (BCL). With our study, we wanted to show how the design and testing of the new panel is taking place and show the benefits of the new 10-color panel. We first tested the Ab performance we wanted to use in the new panel. Eight Ab was checked previously in the framework of testing the 14-color panel for low-cellular samples, and 2 Ab was subsequently tested. We also subsequently tested the Ab CD23-APC-R700 performance, because of Ab CD23-APC-AF700, which did not work well. After testing the Ab performance, we made the flow cytometer settings, compensation and Ab titration. In the end, a new 10-color panel was tested on 48 samples. Its performance was checked on 10 samples of reactive lymphocytic proliferation (RLP) and on 38 BCL samples. We included the most common BCLs, which are analyzed daily in the laboratory: follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphatic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), marginal zone lymphoma (MZL). A new 10-color panel was also tested on 2 cases of composite lymphomas. With the new panel, we got the same results as with the routine 4-color panel, confirming that the new 10-color base panel is suitable for use in day-to-day BCL routine diagnostics.